A.R.T. Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-123,571
Closed -$1.35M 1567
2019
Q2
$1.35M Sell
123,571
-19,674
-14% -$220K 0.08% 348
2019
Q1
$1.62M Buy
143,245
+41,911
+41% +$468K 0.1% 313
2018
Q4
$879K Buy
+101,334
New +$1.16M 0.06% 488
2018
Q3
Sell
-47,752
Closed -$764K 1536
2018
Q2
$764K Buy
47,752
+31,641
+196% +$468K 0.03% 751
2018
Q1
$208K Buy
+16,111
New +$201K 0.01% 1259
2017
Q1
Sell
-103,759
Closed -$1.33M 1558
2016
Q4
$1.33M Buy
+103,759
New +$1.31M 0.08% 395
2016
Q3
Sell
-363,233
Closed -$3.98M 888
2016
Q2
$3.98M Buy
363,233
+126,087
+53% +$1.23M 0.2% 127
2016
Q1
$2.17M Buy
237,146
+138,265
+140% +$1.14M 0.1% 297
2015
Q4
$959K Sell
98,881
-72,954
-42% -$705K 0.05% 583
2015
Q3
$1.5M Buy
171,835
+8,351
+5% +$77.9K 0.06% 489
2015
Q2
$1.65M Buy
163,484
+101,216
+163% +$1.18M 0.06% 529
2015
Q1
$834K Buy
+62,268
New +$817K 0.03% 728
2013
Q3
Sell
-278,054
Closed -$2.31M 1389
2013
Q2
$2.31M Buy
+278,054
New +$3.37M 0.08% 363

Other funds holding IRWD

A.R.T. Advisors's IRWD Position: Q3 2019 in Review

A.R.T. Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2019, closing a stake of 123,571 shares — an estimated $1.35M sold.

A.R.T. Advisors first reported a position in IRWD in Q2 2013 and held it in 13 quarters. The position peaked at $3.98M in Q2 2016. 164 funds tracked by Wall St. Rank hold IRWD as of Q3 2019.

  • A.R.T. Advisors reported no remaining Ironwood Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 123,571 Ironwood Pharmaceuticals shares in Q3 2019, an estimated $1.35M.
  • A.R.T. Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • A.R.T. Advisors's Ironwood Pharmaceuticals position peaked at $3.98M in Q2 2016.
  • 164 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.